The Motley Fool··Prosper Junior BakinyCRISPR Therapeutics Seen Doubling on Pipeline Momentum, But Execution Risk Looms
Piper Sandler's $110 price target for CRISPR Therapeutics suggests 100%+ upside, backed by CTX611 anticoagulant data and Casgevy expansion. Significant clinical and execution risks remain.
VRTXCRSPclinical trialsgene therapy